Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Olaf Heidenreich

Principal Investigator
Olaf joined the Princess Máxima Center in 2018 and leads a research team that focuses on the role of fusion genes in leukemia.

Olaf Heidenreich received a PhD degree from the University of Göttingen. During this time he worked on catalytic RNAs with Fritz Eckstein at the Max Planck Institute for Experimental Medicine. After a postdoc at the Scripps Research Institute in La Jolla, California, he was e a senior research associate at the Medical School Hannover and a lecturer at the University of Tübingen. In 2007, he joined the Northern Institute for Cancer Research at Newcastle University as a Senior Lecturer and became a Professor of Molecular Haematology in 2012. In 2018, he joined the Princess Máxima Center as senior PI.  His research interests focus on leukaemic fusion genes, their impact on malignant self-renewal and their exploitation as cancer-specific therapeutic targets.

  • Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML

    • apr. 2024
    • Vania, Lo Presti, et al
    • Journal for ImmunoTherapy of Cancer
  • Gene regulatory network analysis predicts cooperating transcription factor regulons required for FLT3-ITD+ AML growth

    • dec. 2023
    • Daniel J L, Coleman, et al
    • Cell reports
  • Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression

    • dec. 2023
    • Kristian L, Juul-Dam, et al
    • European journal of medical genetics
  • A multidimensional analysis reveals distinct immune phenotypes and tertiary lymphoid structure-like aggregates in the bone marrow of pediatric acute myeloid leukemia

    • okt. 2023
    • Joost B, Koedijk, et al
    • medRxiv : the preprint server for health sciences
  • Acute myeloid leukemias with UBTF tandem duplications are sensitive to Menin inhibitors

    • okt. 2023
    • Juan Martin, Barajas, et al
    • Blood
View all publications